Credit Suisse Group cut shares of Gilead Sciences (NASDAQ:GILD) from an outperform rating to a neutral rating in a research note released on Wednesday. Credit Suisse Group currently has $80.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $74.35.

GILD has been the subject of a number of other reports. Argus raised shares of Gilead Sciences from a hold rating to a buy rating and set a $100.00 target price for the company in a research note on Thursday, August 31st. Vetr downgraded shares of Gilead Sciences from a strong-buy rating to a buy rating and set a $82.15 target price for the company. in a research note on Monday, August 28th. Wells Fargo & Company boosted their target price on shares of Gilead Sciences from $73.00 to $81.00 and gave the stock a market perform rating in a research note on Wednesday, September 6th. Oppenheimer assumed coverage on shares of Gilead Sciences in a research note on Thursday, October 5th. They issued a market perform rating for the company. Finally, Mizuho boosted their target price on shares of Gilead Sciences from $77.00 to $83.00 and gave the stock a buy rating in a research note on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Gilead Sciences has an average rating of Buy and an average price target of $85.03.

Shares of Gilead Sciences (GILD) traded down $0.43 during midday trading on Wednesday, hitting $73.58. 1,523,484 shares of the company’s stock were exchanged, compared to its average volume of 9,211,087. Gilead Sciences has a one year low of $63.76 and a one year high of $86.27. The company has a market capitalization of $97,121.10, a P/E ratio of 7.76, a PEG ratio of -1.25 and a beta of 1.13. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. During the same period in the previous year, the firm posted $2.75 earnings per share. The company’s revenue was down 13.2% on a year-over-year basis. research analysts expect that Gilead Sciences will post 8.53 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.83%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s dividend payout ratio is currently 23.69%.

In related news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $74.98, for a total transaction of $5,498,508.34. Following the completion of the transaction, the insider now owns 3,070,099 shares in the company, valued at $230,196,023.02. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Gregg H. Alton sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $82.65, for a total transaction of $2,066,250.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 494,999 shares of company stock valued at $37,404,139. Corporate insiders own 1.30% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Nichols & Pratt Advisers LLP MA boosted its holdings in Gilead Sciences by 21.7% during the first quarter. Nichols & Pratt Advisers LLP MA now owns 162,742 shares of the biopharmaceutical company’s stock worth $11,042,000 after purchasing an additional 28,965 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Gilead Sciences by 76.1% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 106,700 shares of the biopharmaceutical company’s stock worth $7,247,000 after purchasing an additional 46,100 shares during the last quarter. Thornburg Investment Management Inc. raised its position in Gilead Sciences by 121.8% during the first quarter. Thornburg Investment Management Inc. now owns 1,033,766 shares of the biopharmaceutical company’s stock worth $70,213,000 after acquiring an additional 567,650 shares in the last quarter. GHP Investment Advisors Inc. raised its position in Gilead Sciences by 19.3% during the first quarter. GHP Investment Advisors Inc. now owns 3,499 shares of the biopharmaceutical company’s stock worth $238,000 after acquiring an additional 567 shares in the last quarter. Finally, Airain ltd raised its position in Gilead Sciences by 38.1% during the first quarter. Airain ltd now owns 402,196 shares of the biopharmaceutical company’s stock worth $27,317,000 after acquiring an additional 110,923 shares in the last quarter. Hedge funds and other institutional investors own 75.94% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Gilead Sciences (GILD) Lowered to Neutral at Credit Suisse Group” was posted by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.watchlistnews.com/gilead-sciences-gild-lowered-to-neutral-at-credit-suisse-group/1776347.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.